Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (11-20 of 144) with videos related to

Pageof 15
Sort By:
Fundamental & Clinical Pharmacology|November 16, 2007
Setting a new standard in achieving superior efficacy: ezetimibe + simvastatinMichel Farnier
Expert Review of Cardiovascular Therapy|June 2, 2012
Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemiaMichel Farnier
Vascular Health and Risk Management|February 3, 2009
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribingMichel Farnier
Expert Opinion on Drug Safety|March 23, 2011
Safety review of combination drugs for hyperlipidemiaMichel Farnier
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacksMichel Farnier
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 31, 2011
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implicationsMichel Farnier
Expert Opinion on Pharmacotherapy|June 15, 2007
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?Michel Farnier
Expert Review of Cardiovascular Therapy|November 14, 2015
An evaluation of alirocumab for the treatment of hypercholesterolemiaMichel Farnier
Presse Medicale (Paris, France : 1983)|October 3, 2018
[New guidelines on dyslipidemia management: Comparison of French (HAS) and European (ESC/EAS) guidelines]Michel Farnier
European Journal of Preventive Cardiology|August 25, 2025
High Adherence to High-Intensity Statins after Acute Myocardial Infarction: the "PACMAN Pathway"Francois Schiele, Michel Farnier
Pageof 15

Showing results (11-20 of 144) with videos related to

Sort By:
Pageof 15
Fundamental & Clinical Pharmacology|November 16, 2007
Setting a new standard in achieving superior efficacy: ezetimibe + simvastatinMichel Farnier
Expert Review of Cardiovascular Therapy|June 2, 2012
Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemiaMichel Farnier
Vascular Health and Risk Management|February 3, 2009
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribingMichel Farnier
Expert Opinion on Drug Safety|March 23, 2011
Safety review of combination drugs for hyperlipidemiaMichel Farnier
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacksMichel Farnier
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 31, 2011
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implicationsMichel Farnier
Expert Opinion on Pharmacotherapy|June 15, 2007
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?Michel Farnier
Expert Review of Cardiovascular Therapy|November 14, 2015
An evaluation of alirocumab for the treatment of hypercholesterolemiaMichel Farnier
Presse Medicale (Paris, France : 1983)|October 3, 2018
[New guidelines on dyslipidemia management: Comparison of French (HAS) and European (ESC/EAS) guidelines]Michel Farnier
European Journal of Preventive Cardiology|August 25, 2025
High Adherence to High-Intensity Statins after Acute Myocardial Infarction: the "PACMAN Pathway"Francois Schiele, Michel Farnier
Pageof 15